Cardiovascular Pathology
Volume 19, Issue 3 , Pages 147-152 , May 2010

Large animal models for diastolic dysfunction and diastolic heart failure—a review of the literature

  • Shay Dubi

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Yaron Arbel

      Affiliations

    • Department of Internal Medicine ‘D’, Tel Aviv Sourasky Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author. Tel Aviv Sourasky Medical Center, Weizman 6, Tel Aviv 69513, Israel. Tel.: +972 524 266151; fax: +972 3 6973259.

Received 13 February 2008 ,Revised 11 August 2008 ,Accepted 16 December 2008.

References 

  1. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118–2121
  2. Senni M, Redfield MM. Heart failure with preserved systolic function: A different natural history?. J Am Coll Cardiol. 2001;38:1277–1282
  3. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–1955
  4. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol. 2001;88:530–533
  5. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22:318–325
  6. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 1990;81:III1–III7
  7. Borbely A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJM, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774–781
  8. Kass DA, Bronzwaer JGF, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res. 2004;94:1533–1542
  9. Sweitzer NK, Stevenson LW. Diastolic heart failure: miles to go before we sleep. Am J Med. 2000;109:683
  10. Zile MR, Baicu CF, Bonnema DD. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis. 2005;47:307–313
  11. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank–Starling mechanism. J Am Coll Cardiol. 1991;17:1065–1072
  12. Little WC, Wesley-Farrington DJ, Hoyle J, Brucks S, Robertson S, Kitzman DW, et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol. 2004;43:288–293
  13. Little WC. Hypertensive pulmonary oedema is due to diastolic dysfunction. Eur Heart J. 2001;22:1961–1964
  14. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959
  15. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart. 2006;92:712–718
  16. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387–1393
  17. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J. 1998;19:990–1003
  18. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation. 2001;104:779–782
  19. Vasan RS, Benjamin EJ. Diastolic heart failure—no time to relax. N Engl J Med. 2001;344:56–59
  20. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–e82
  21. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–1443
  22. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  23. Sabbah HN. The cardiac support device and the Myosplint: treating heart failure by targeting left ventricular size and shape. Ann Thorac Surg. 2003;75:S13–S19
  24. Yarbrough WM, Spinale FG. Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol. 2003;10:77–86
  25. Page I. A method for producing persistent hypertension by cellophane. Science. 1939;89:273–274
  26. Hart CY, Meyer DM, Tazelaar HD, Grande JP, Burnett JC, Housmans PR, et al. Load versus humoral activation in the genesis of early hypertensive heart disease. Circulation. 2001;104:215–220
  27. Maniu CV, Meyer DM, Redfield MM. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension. Hypertension. 2002;40:528–534
  28. Munagala VK, Hart CYT, Burnett JC, Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation. 2005;111:1128–1135
  29. Hayashida W, Donckier J, Van Mechelen H, Charlier AA, Pouleur H. Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovasc Res. 1997;33:54
  30. Hayashida W, Donckier J, Van Mechelen H, Charlier AA, Pouleur H. Load-sensitive diastolic relaxation in hypertrophied left ventricles. Am J Physiol Heart Circ Physiol. 1998;274:H609–H615
  31. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51(2):289–295
  32. Abrahams C, Janicki JS, Weber KT. Myocardial hypertrophy in Macaca fascicularis. Structural remodeling of the collagen matrix. Lab Invest. 1987;56:676–683
  33. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002;55:76
  34. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II: Causal mechanisms and treatment. Circulation. 2002;105:1503–1508
  35. Yasuda S, Goto Y, Shishido T. Uncoupling between left ventricular contractility and relaxation after direct-current counter shocks. Basic Res Cardiol. 1999;94:261–266
  36. Hirsch JC, Borton AR, Albayya FP, Russell MW, Ohye RG, Metzger JM. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2004;286:H2314–H2321
  37. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation. 2006;114:1821–1828
  38. Aoyagi T, Mirsky I, Flanagan MF, Currier JJ, Colan SD, Fujii AM. Myocardial function in immature and mature sheep with pressure-overload hypertrophy. Am J Physiol. 1992;262:H1036–H1048
  39. Schubert A, Walther T, Falk V, Binner C, Loscher N, Kanev A, et al. Extracellular matrix gene expression correlates to left ventricular mass index after surgical induction of left ventricular hypertrophy. Basic Res Cardiol. 2001;96:381–387
  40. Ye Y, Gong G, Ochiai K, Liu J, Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation. 2001;103:1570–1576
  41. Malo O, Carrier M, Shi YF, Tardif JC, Tanguay JF, Perrault LP. Specific alterations of endothelial signal transduction pathways of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2003;42:275–286
  42. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. PNAS. 2000;97:2809–2813

 Disclosure: Shay Dubi is a shareholder in CorAssist Cardiovascular Limited.

PII: S1054-8807(08)00189-0

doi: 10.1016/j.carpath.2008.12.008

Cardiovascular Pathology
Volume 19, Issue 3 , Pages 147-152 , May 2010

Article Tools